ERBB2 and breast carcinoma: For example, a recent report showing highly aggressive (“triple negative”) breast cancer was vulnerable to double inhibition of HER2/mTORC1 (HER2 by trastuzumab and mTORC1 by a selective inhibitor, INK-128) [50].